Odonate announces 'positive' results but faces investor backlash; Aslan is once again recruiting clinical trial participants after months-long wait amid the pandemic
Odonate Therapeutics announced “positive top-line results” from a Phase III study of their lead cancer drug. And sure enough, tesetaxel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
